Autoimmune Hemolytic Anemia as a Complication of Nivolumab T
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Immune checkpoint inhibitor nivolumab is a fully human IgG4 monoclonal antibody against programmed death- (PD-1) receptor that blocks interactions between PD-1 and its ligands on tumor cells to prevent T cell exhaustion in patients with cancer. However, this release of check on the immune system can also unleash it against the body's own tissues leading to an autoimmune phenomenon which is the main mechanism for the adverse effects associated with nivolumab. Common clinical manifestations due to this autoimmune phenomenon include pneumonitis, hepatitis, colitis, hypophysitis, pruritis, arthritis, and nephritis. Autoimmune hemolytic anemia is recently being recognized as another autoimmune adverse effect of this treatment.....

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126613/
F●●●●a A●●●s and 3 others like this
Like
Comment
Share